CR8439A - METHOD FOR IMPROVING THE EFFECTIVENESS OF RADIO THERAPEUTIC DRUGS LABELED - Google Patents
METHOD FOR IMPROVING THE EFFECTIVENESS OF RADIO THERAPEUTIC DRUGS LABELEDInfo
- Publication number
- CR8439A CR8439A CR8439A CR8439A CR8439A CR 8439 A CR8439 A CR 8439A CR 8439 A CR8439 A CR 8439A CR 8439 A CR8439 A CR 8439A CR 8439 A CR8439 A CR 8439A
- Authority
- CR
- Costa Rica
- Prior art keywords
- radio
- improving
- effectiveness
- labeled
- therapeutic drugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se dan a conocer drogas radiorotuladas y metodos para mejorar su eficacia mediante el uso de un radiosensibilizador tal que el radiosensibilizador tanto forma parte de la droga radiorotulada mediante el acople directo del rediosensibilizador a la droga radiorotulada como produciendo una mezcla de la droga radiorotulada y un analogo de la droga con el radiosensibilizador acoplado a la droga en lugar del radiorotuloRadio-labeled drugs and methods for improving their efficacy are disclosed through the use of a radiosensitizer such that the radiosensitizer is both part of the radio-labeled drug by direct coupling of the radio-sensitized rediosensitizer and producing a mixture of the radio-labeled drug and an analogue of the drug with the radiosensitizer coupled to the drug instead of the radio
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52847303P | 2003-12-11 | 2003-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR8439A true CR8439A (en) | 2006-12-07 |
Family
ID=34676848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8439A CR8439A (en) | 2003-12-11 | 2006-06-07 | METHOD FOR IMPROVING THE EFFECTIVENESS OF RADIO THERAPEUTIC DRUGS LABELED |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1691838A2 (en) |
JP (1) | JP2007528874A (en) |
KR (1) | KR20060118542A (en) |
CN (1) | CN101031319A (en) |
AU (1) | AU2004296621A1 (en) |
BR (1) | BRPI0417517A (en) |
CA (1) | CA2546057A1 (en) |
CR (1) | CR8439A (en) |
EC (1) | ECSP066618A (en) |
IL (1) | IL175674A0 (en) |
MX (1) | MXPA06006683A (en) |
NO (1) | NO20063207L (en) |
RU (1) | RU2006124510A (en) |
WO (1) | WO2005056058A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI568453B (en) * | 2011-11-22 | 2017-02-01 | 原創生醫股份有限公司 | A drug carrier with chelating complex micelles and the application thereof |
CN106975078B (en) * | 2017-03-31 | 2020-11-10 | 国家纳米科学中心 | Application of nano material containing gadolinium polytungstate as sensitizer |
WO2024013272A1 (en) * | 2022-07-13 | 2024-01-18 | Universite De Montpellier | Combined therapy with nanoparticles and radiopharmaceuticals |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR022404A1 (en) * | 1999-01-25 | 2002-09-04 | Photogen Inc | METHOD AND AGENTS FOR IMPROVED RADIATION THERAPY |
AU2001249608A1 (en) * | 2000-03-28 | 2001-10-08 | Beth Israel Deaconess Medical Center | Bladder cancer-specific peptides for diagnosis and therapy |
IL157142A0 (en) * | 2001-01-29 | 2004-02-08 | Idec Pharma Corp | Modified antibodies and methods of use |
WO2004016753A2 (en) * | 2002-08-15 | 2004-02-26 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
-
2004
- 2004-12-13 AU AU2004296621A patent/AU2004296621A1/en not_active Abandoned
- 2004-12-13 KR KR1020067011322A patent/KR20060118542A/en not_active Application Discontinuation
- 2004-12-13 WO PCT/IB2004/004428 patent/WO2005056058A2/en active Search and Examination
- 2004-12-13 RU RU2006124510/15A patent/RU2006124510A/en not_active Application Discontinuation
- 2004-12-13 CA CA002546057A patent/CA2546057A1/en not_active Abandoned
- 2004-12-13 JP JP2006543664A patent/JP2007528874A/en not_active Withdrawn
- 2004-12-13 BR BRPI0417517-4A patent/BRPI0417517A/en not_active IP Right Cessation
- 2004-12-13 EP EP04817629A patent/EP1691838A2/en not_active Withdrawn
- 2004-12-13 CN CNA2004800369951A patent/CN101031319A/en active Pending
- 2004-12-13 MX MXPA06006683A patent/MXPA06006683A/en unknown
-
2006
- 2006-05-16 IL IL175674A patent/IL175674A0/en unknown
- 2006-06-07 CR CR8439A patent/CR8439A/en unknown
- 2006-06-08 EC EC2006006618A patent/ECSP066618A/en unknown
- 2006-07-10 NO NO20063207A patent/NO20063207L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2005056058A2 (en) | 2005-06-23 |
BRPI0417517A (en) | 2007-03-06 |
IL175674A0 (en) | 2006-09-05 |
RU2006124510A (en) | 2008-01-20 |
NO20063207L (en) | 2006-07-10 |
KR20060118542A (en) | 2006-11-23 |
EP1691838A2 (en) | 2006-08-23 |
WO2005056058A3 (en) | 2006-04-13 |
CN101031319A (en) | 2007-09-05 |
ECSP066618A (en) | 2006-10-25 |
AU2004296621A1 (en) | 2005-06-23 |
MXPA06006683A (en) | 2006-08-11 |
JP2007528874A (en) | 2007-10-18 |
CA2546057A1 (en) | 2005-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200300245A (en) | COMBINED ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS | |
DOP2017000177A (en) | NEW ANTI-CD38 ANTIBODIES FOR CANCER TREATMENT | |
MY157661A (en) | Bendamustine pharmaceutical compositions | |
HN2003000182A (en) | DERIVATIVES OF BENZOCONDENSED HETEROARILAMIDE OF USEFUL TIENOPIRIDINS AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE SAME AND METHOD FOR USE | |
AR049985A1 (en) | COMBINATION TREATMENT FOR NON-HEMATOLOGICAL MALIGNAL DISEASES | |
HN2003000039A (en) | 2- (PIRIMIDIN-2-ILAMINO) -PIRIDO [2,3-d] PIRIMIDIN-7-ONAS | |
ATE432279T1 (en) | TRICYCLIC DELTA OPIOID MODULATORS | |
CR20140108A (en) | CYCLOPROPANOAMINE COMPOUND | |
CR8380A (en) | METHODS FOR PREPARING AND USING NEW DEVELOPMENTS OF MOTHER CELLS AND THEIR ASSEMBLIES | |
UY28757A1 (en) | SUBSTITUTED PIRAZOLINE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICATIONS | |
CR8519A (en) | NEW FUSIONATED PIRROLOCARBAZOLS | |
PA8654601A1 (en) | CYTOTOXIC AGENTS UNDERSTANDING NEW TAXANS | |
GT200500127A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER | |
UA94036C2 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
UY26456A1 (en) | COMPOUNDS THAT FIX THE G-QUADRUPLEX STRUCTURE OF TELOMERES, TRIAZINS FOR THE APPLICATION OF SUCH COMPOUNDS, THE USE OF SUCH COMPOUNDS AS PHARMACEUTICAL PRODUCTS AND INCLUDING THERAPEUTICAL ASSOCIATIONS. | |
MX2008008413A (en) | Pharmaceutical composition for the treatment of nail diseases. | |
AR032293A1 (en) | PHARMACEUTICAL CASE | |
CR8439A (en) | METHOD FOR IMPROVING THE EFFECTIVENESS OF RADIO THERAPEUTIC DRUGS LABELED | |
BR0209645A (en) | Oxazole and furopyrimidines and their use as medicines | |
DK1699480T3 (en) | Allogeneic therapeutic tumor agent | |
NI200800216A (en) | USE OF TPO PEPTIDIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS IN THE TREATMENT OF ANEMIA | |
Marcellin et al. | Viral hepatitis: impressive advances but still a long way to eradication of the disease | |
CO5050343A1 (en) | COMBINATION OF FENTOLAMINE AND APOMORPHINE FOR THE TREATMENT OF HUMAN SEXUAL FUNCTION AND DYSFUNCTION | |
CO2022017112A2 (en) | N-cyanopyrrolidines with activity as ubiquitin-specific peptidase inhibitors 30 | |
AR048068A1 (en) | PIPERAZINAS DERIVED FROM UREA FOR THE TREATMENT OF ENDOMETRIOSIS |